{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:48:26Z","timestamp":1778600906025,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Positive antiphospholipid antibodies (aPLs) and chronic hypertension (CH) in pregnancy are important causes of maternal and neonatal morbidity and mortality. However, there are no relevant studies on the treatment of aPL-positive pregnant women with CH. This study aimed to determine the effect of low-dose aspirin (LDA) plus low-molecular-weight heparin (LMWH) on maternal and perinatal outcomes in persistently aPL-positive pregnant women with CH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was performed at the First Affiliated Hospital of Dalian Medical University in Liaoning, China, from January 2018 to December 2021. Pregnant women diagnosed CH and persistently positive aPL who had no autoimmune disease such as systemic lupus erythematosus, antiphospholipid syndrome were recruited and divided into control group (LDA and LWMH were not used), LDA group (LDA was used) and LDA plus LMWH group (both LDA and LMWH were used) according to whether they use LDA and\/or LMWH. A total of 81 patients were enrolled, including 40 patients in the control group, 19 patients in the LDA group, and 22 patients in the LDA plus LMWH group. The maternal and perinatal outcomes of LDA plus LMWH therapy were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with control group, the rate of severe preeclampsia in LDA group (65.00% vs. 31.58%, <jats:italic>p<\/jats:italic>\u2009=\u20090.016) and LDA plus LMWH group (65.00% vs. 36.36%, <jats:italic>p<\/jats:italic>\u2009=\u20090.030) had a statistically significant reduction. Compared with control group, the rate of fetal loss in LDA group (35.00% vs. 10.53%, <jats:italic>p<\/jats:italic>\u2009=\u20090.014) and LDA plus LMWH group (35.00% vs. 0.00%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) had a statistically significant reduction. Compared with control group, the rate of live birth in LDA group (65.00% vs. 89.74%, <jats:italic>p<\/jats:italic>\u2009=\u20090.048) and LDA plus LMWH group (65.00% vs. 100.00%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) had a statistically significant increased. Compared withcontrol group, the incidence of early-onset preeclampsia (47.50% vs. 36.84%, <jats:italic>p<\/jats:italic>\u2009=\u20090.008) and early-onset severe preeclampsia (47.50% vs. 13.64%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) in the LDA plus LMWH group decreased and were statistically different. Furthermore, we also found that LDA or LDA plus LMWH hadn't increase the rate of blood loss and placental abruption.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both LDA and LDA combined with LMWH could decrease the incidence of severe preeclampsia, decrease the rate of foetal loss, increase the rate of live birth. However, LDA plus LWMH could reduce and delay the onset of severe preeclampsia, prolong the gestational age and increase the rate of full-term delivery, improve the maternal and perinatal outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1148547","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T05:49:36Z","timestamp":1683265776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Maternal and perinatal outcomes of low-dose aspirin plus low-molecular-weight heparin therapy on antiphospholipid antibody-positive pregnant women with chronic hypertension"],"prefix":"10.3389","volume":"11","author":[{"given":"Shangqin","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjie","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nannan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12194","DOI":"10.1016\/j.preghy.2017.10.011","article-title":"Pregnancy outcomes in women with previous gestational hypertension: a cohort study to guide counselling and management","author":"Nzelu","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"B2","doi-asserted-by":"publisher","first-page":"217.e211","DOI":"10.1016\/j.ajog.2020.08.019","article-title":"The impact of the definition of preeclampsia on disease diagnosis and outcomes: a retrospective cohort study","volume":"224","author":"Reddy","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ijgo.13763","article-title":"A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: compiled by the pregnancy and non-communicable diseases committee of FIGO (the international federation of gynecology and obstetrics)","volume":"154","author":"Poon","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: iSSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/uog.17493","article-title":"Chronic hypertension and adverse pregnancy outcome: a cohort study","volume":"50","author":"Panaitescu","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1515\/cclm-2021-0692","article-title":"Anti-phosphatidyl-serine\/prothrombin antibodies (aPS\/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?","volume":"59","author":"Tonello","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B7","first-page":"299","article-title":"Prevalence of various antiphospholipid antibodies in pregnant women","volume":"49","author":"Fialov\u00e1","year":"2000","journal-title":"Physiol Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0049-3848(19)30366-4","article-title":"Managing antiphospholipid syndrome in pregnancy","volume":"181","author":"Schreiber","year":"2019","journal-title":"Thromb Res"},{"key":"B9","first-page":"541","article-title":"The association of antiphospholipid antibodies with severe preeclampsia","volume":"73","author":"Branch","year":"1989","journal-title":"Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/bmj.38380.674340.E0","article-title":"Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies","volume":"330","author":"Duckitt","year":"2005","journal-title":"Br Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/jcm11030675","article-title":"Diagnosis and management of obstetric antiphospholipid syndrome: a comprehensive review","volume":"11","author":"Alijotas-Reig","year":"2022","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/OGX.0000000000000942","article-title":"Gestational hypertension and preeclampsia: an overview of national and international guidelines","volume":"76","author":"Tsakiridis","year":"2021","journal-title":"Obstet Gynecol Surv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00404-021-06178-5","article-title":"Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update","volume":"304","author":"Li","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0095-5108(18)30288-4","article-title":"Understanding prostaglandin metabolites and platelet-activating factor in the pathophysiology and treatment of the antiphospholipid syndrome","volume":"22","author":"Silver","year":"1995","journal-title":"Clin Perinatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/0002-9378(91)90695-N","article-title":"The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy","volume":"164","author":"el-Roeiy","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"B16","first-page":"614","article-title":"Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience","volume":"80","author":"Branch","year":"1992","journal-title":"Obstet Gynecol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/01.AOG.0000559202.88943.30","article-title":"ACOG Practice bulletin No. 203: chronic hypertension in pregnancy","volume":"133","author":"Alex Vidaeff","year":"2019","journal-title":"Obstet Gynecol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: aCOG practice bulletin, number 222","volume":"135","author":"Jimmy Espinoza","year":"2020","journal-title":"Obstet Gynecol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.preghy.2014.02.001","article-title":"The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP","volume":"4","author":"Tranquilli","year":"2014","journal-title":"Pregnancy Hypertens"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"2","author":"Harris","year":"1983","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0140-6736(15)00838-7","article-title":"Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN maternal mortality estimation inter-agency group","volume":"387","author":"Alkema","year":"2016","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1016\/j.jmgm.2012.12.013","article-title":"Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM\/MM calculations","author":"T\u00f3th","year":"2013","journal-title":"J Mol Graph Model"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910730","article-title":"Molecular mechanism of the anti-inflammatory action of heparin","volume":"22","author":"Litov","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1080\/14767058.2020.1760834","article-title":"Low-dose low-molecular-weight heparin prophylaxis against obstetrical complications in pregnancies with metabolic and immunological disorder-associated placental inflammation","volume":"35","author":"Beksac","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"Cd012852","DOI":"10.1002\/14651858.CD12852.pub2","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","volume":"5","author":"Hamuly\u00e1k","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/14767058.2017.1404979","article-title":"Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials","volume":"32","author":"Lu","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"585.e581","DOI":"10.1016\/j.ajog.2017.07.038","article-title":"Aspirin for evidence-based preeclampsia prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history","volume":"217","author":"Poon","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1126","DOI":"10.1016\/j.ajog.2020.11.006","article-title":"Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis","volume":"226","author":"Cruz-Lemini","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.5114\/aoms\/136518","article-title":"Efficacy and safety of low-dose aspirin combined with low-molecular-weight heparin in treatment of preeclampsia: a meta-analysis and systematic review","volume":"18","author":"Wu","year":"2022","journal-title":"Arch Med Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/etm.2020.9489","article-title":"Aspirin and heparin in the treatment of recurrent spontaneous abortion associated with antiphospholipid antibody syndrome: a systematic review and meta-analysis","volume":"21","author":"Yu","year":"2021","journal-title":"Exp Ther Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e26264","DOI":"10.1097\/MD.0000000000026264","article-title":"Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels","volume":"100","author":"Shi","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"83104807","DOI":"10.1016\/j.amsu.2022.104807","article-title":"Effects of low-dose aspirin and heparin on the pregnancy outcome in women with antiphospholipid syndrome","author":"Baiazid","year":"2022","journal-title":"Ann Med Surg (London)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.10.014","article-title":"Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials","author":"Liu","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ijgo.13535","article-title":"Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: a stratified cohort study","volume":"154","author":"Zhang","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1177\/0961203318787032","article-title":"Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome","volume":"27","author":"Yelnik","year":"2018","journal-title":"Lupus"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1148547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T05:49:41Z","timestamp":1683265781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1148547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":36,"alternative-id":["10.3389\/fped.2023.1148547"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1148547","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1148547"}}